Crinetics Pharmaceuticals (Crinetics Pharmaceuticals) Effective Interest Rate on Debt % : 0.00% (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Crinetics Pharmaceuticals Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Crinetics Pharmaceuticals's annualized positive value of Interest Expense for the quarter that ended in Mar. 2024 was $0.00 Mil. Crinetics Pharmaceuticals's average total debt for the quarter that ended in Mar. 2024 was $52.12 Mil. Therefore, Crinetics Pharmaceuticals's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2024 was 0.00%.

Crinetics Pharmaceuticals Effective Interest Rate on Debt % Historical Data

The historical data trend for Crinetics Pharmaceuticals's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Crinetics Pharmaceuticals Effective Interest Rate on Debt % Chart

Crinetics Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Effective Interest Rate on Debt %

Get a 7-Day Free Trial

Crinetics Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Effective Interest Rate on Debt %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Crinetics Pharmaceuticals's Effective Interest Rate on Debt %

For the Biotechnology subindustry, Crinetics Pharmaceuticals's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Crinetics Pharmaceuticals's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Crinetics Pharmaceuticals's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Crinetics Pharmaceuticals's Effective Interest Rate on Debt % falls into.

Crinetics Pharmaceuticals Effective Interest Rate on Debt % Calculation

Crinetics Pharmaceuticals's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2023 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (A: Dec. 2022 )	+	Total Debt (A: Dec. 2023 ))	/ count )
=	-1 * 0	/	( (3.075	+	51.728)	/ 2 )
=	-1 * 0	/	27.4015
=	0.00 %

where

	Total Debt (A: Dec. 2022 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	2.024	+	1.051
=	3.075

	Total Debt (A: Dec. 2023 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	47.555	+	4.173
=	51.728

Crinetics Pharmaceuticals's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2024 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (Q: Dec. 2023 )	+	Total Debt (Q: Mar. 2024 ))	/ count )
=	-1 * 0	/	( (51.728	+	52.504)	/ 2 )
=	-1 * 0	/	52.116
=	0.00 %

where

	Total Debt (Q: Dec. 2023 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	47.555	+	4.173
=	51.728

	Total Debt (Q: Mar. 2024 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	46.712	+	5.792
=	52.504

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Mar. 2024) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.

Crinetics Pharmaceuticals (NAS:CRNX) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.

Crinetics Pharmaceuticals Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Crinetics Pharmaceuticals's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.

Crinetics Pharmaceuticals (Crinetics Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Crinetics Pharmaceuticals Inc (NAS:CRNX) » Definitions » Effective Interest Rate on Debt %

Comparable Companies

Traded in Other Exchanges

6Z4:Germany

Address

10222 Barnes Canyon Road, Building No. 2, San Diego, CA, USA, 92121

Website

https://www.crinetics.com

Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.

Executives

Stephen F. Betz	officer: Chief Scientific Officer	10222 BARNES CANYON ROAD, BUILDING 2, SAN DIEGO CA 92121
Dana Pizzuti	officer: Chief Development Officer	C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BUILDING 2, SAN DIEGO CA 92121
Marc Wilson	officer: See Remarks	6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Richard Scott Struthers	director, officer: See Remarks	C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO CA 92121
Alan Seth Krasner	officer: Chief Medical Officer	C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO CA 92121
Vivaldi Coelho Rogerio	director	225 SECOND AVENUE, WALTHAM MA 02451
Jeff E. Knight	officer: Chief Operating Officer	CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BUILDING 2, SAN DIEGO CA 92121
Matthew K Fust	director	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Caren Deardorf	director	C/O MAGENTA THERAPEUTICS, INC., 100 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
James Hassard	officer: Chief Commercial Officer	177 E COLORADO BLVD, STE 700, PASADENA CA 91105
Ajay Madan	officer: Chief Development Officer	C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BLDG. 2, SAN DIEGO CA 92121
Camille L Bedrosian	director	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Vivo Capital Fund Viii, L.p.	10 percent owner	505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301
Perceptive Advisors Llc	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003